| abstract |
Treatment, prevention, or amelioration of one or more symptoms of cell surface protease-related diseases, including MTSP-related, urokinase-type plasminogen activator (uPA) or endotheliase-related diseases Conjugates, compositions and methods for providing are provided. The conjugates used in the compositions and methods are peptidic conjugates containing therapeutic agents, including cytotoxic agents. |